Navigation Links
Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

ept's researchers to discover and rapidly test the effect of small molecules on pathways and molecular targets crucial to apoptosis, and gain insights into their potential as new anticancer agents. This screening technology is particularly versatile and can be adapted for almost any cell type that can be cultured, as well as measure caspase activation inside multiple cell types (e.g., cancer cells, immune cells, or cell lines from different organ systems or genetically engineered cells). This allows researchers to find potential drug candidates that are selective for specific cancer types, which may help identify candidates that provide increased therapeutic benefit and reduced toxicity.

EpiCept has identified several families of compounds with potentially novel mechanisms that induce apoptosis in cancer cells. Several compounds from within these families have progressed to lead drug candidate status with proven pre-clinical efficacies in tumor models and identified molecular targets.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. New Report Illuminates Ampligens Unique Mechanism of Action
6. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
7. Myriad Genetics Presents Azixas Mode of Action at AACR
8. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mode Action EpiCept Licensed Cancer Compound Profiled AACR
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
... University of Michigan Health System has selected a new system-wide ... medical to communications devices, wireless phones and pagers for its ... Hospital. "Moving from a facility where numerous beds ... where beds are now separated into multiple rooms, we anticipated ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3New Hospitals to Implement New Communications Technology 2
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... , ... In addition to its existing Doctor of Philosophy in Leadership and ... its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of ... nurses for the highest level of clinical nursing practice. , “Our vision is ...
(Date:8/27/2015)... ... ... North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing ... located at US Highway 19 North and Highlands Boulevard, less than eight miles from the ... project is slated to begin in September 2015. , The new 24-bed facility ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... England, both in terms of lives and money nearly ... report published today by the All Party Parliamentary Group (APPG) ... Lives - concludes that, despite effective treatments, there are 365 ... with unnecessary seizures, and 74,000 people are taking anti-epilepsy drugs ...
... tentative agreement with Delmont Laboratory to introduce its immunotherapeutic ... . According to this initial agreement, Delmont Laboratory will ... manufactures for the final packaging in China. ... agreement is to be signed. This product requires a ...
... data from its Phase IIb study in Alzheimer's disease (AD) ... and treated as diabetes of the brain. ... of amyloid beta plaques in the brain, yet recent research ... the brains of mice gives rise to some of the ...
... Diagnostics today announces that it has completed its ... with BioVeris for approximately $600 million on April ... Diagnostics now owns the patents for Electrochemiluminescence (ECL) ... the human diagnostics field into new market segments ...
... confirmed that the potentially lethal H5N1 strain of bird flu ... the country, the second such incident here in a week. ... the area around Frohburg, near Liepzig, second incidence of the ... ,The discovery followed the confirmation on Sunday of ...
... that air pollution affects women more than men . ... groups of mice with pneumonia. One group was exposed ... filtered air. ,The exposure to ozone significantly ... compared to males, reported science portal SCIENCE A GoGo. ...
Cached Medicine News:Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
Inquire...
Inquire...
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
Medicine Products: